FridayFeb 13, 2026 10:00 am

Groundbreaking Study Uncovers Why Breast Cancer Metastasizes to the Brain

A groundbreaking study led by a pair of researchers from Israel and involving research teams in several countries has discovered why some forms of breast cancer metastasize into the brain and become deadly. Their findings could open new doors in the management of breast cancer and address the needs of patients who are at a higher risk of developing metastases in the brain.  The study, whose findings appeared in the Nature Genetics journal, was led by Professor Uri Ben-David and his colleague Professor Ronit Satchi-Fainaro, both working at Gray Faculty of Medical & Health Sciences in Tel Aviv, Israel. Other researchers who were involved in the study were…

Continue Reading

FridayFeb 13, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit These two announcements paint a picture of a company advancing on multiple fronts LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore…

Continue Reading

FridayFeb 13, 2026 9:00 am

Earth Science Tech Inc. (ETST) Driving Growth Through Strategic Healthcare Integration

ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance. The company’s core operations focus on the health and wellness sector via a vertically integrated portfolio. ETST’s mission centers on building durable shareholder value through regulatory discipline, operational control, and scalable growth platforms. A Hands-On Approach to Portfolio Management Earth Science Tech (OTC: ETST) is redefining the traditional holding company model by building a diversified portfolio designed for long-term sustainability. Unlike passive investment vehicles, ETST takes an active role in its subsidiaries, utilizing hands-on management and disciplined execution to enhance performance across the board.…

Continue Reading

ThursdayFeb 12, 2026 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum. HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through…

Continue Reading

ThursdayFeb 12, 2026 10:00 am

Early Symptoms of Lung Cancer You Could Be Ignoring

Many times, a diagnosis of lung cancer comes late because the early symptoms may be dismissed since they are so subtle and can be mistaken for other illnesses. However, as with any other cancer, catching lung cancer early offers the best chance of getting better treatment outcomes. We explore some of those early warning signs that you may be downplaying.  When you develop a cough that persists for several weeks, don’t be too quick to dismiss it as just an ordinary cough. Many times, that cough could be the result of an infection, an allergy, or pollution or be dismissed as “smoker’s cough.” However, it could also be pointing to something more serious, like lung cancer,…

Continue Reading

TuesdayFeb 10, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM), or SGX301, designed for the treatment of cutaneous T-cell lymphoma. The company has achieved an important safety milestone in its confirmatory phase 3 clinical trial of HyBryte for CTCL treatment. From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin diseases using targeted photodynamic…

Continue Reading

TuesdayFeb 10, 2026 10:00 am

Why the Cost of Health Care in the US is Soaring

While people have been quick to blame health insurers for the skyrocketing cost of health care in the U.S., the reality of the situation is more nuanced, and other factors have played a much bigger role in driving up costs. We explore some of those less-reported drivers of the high cost of health care in the country.  For example, the law caps the rates levied by medical facilities when treating patients on Medicare. However, private insurers aren’t constrained by these laws as they negotiate their rates directly with the health care facilities serving their clients. In order to be more appealing to patients on private insurance policies, hospitals are racing to upgrade…

Continue Reading

MondayFeb 09, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over technologies that are currently available for treating tumors with proton therapy The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers. Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship…

Continue Reading

FridayFeb 06, 2026 10:00 am

New Photodynamic Therapy Offers Hope Against Brain Cancer

A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after a patient has undergone surgery to remove a tumor has elicited excitement as it could provide a way forward in eliminating microscopic cancer tissue that surgeons are unable to see while surgically removing a cancerous tumor from the brain.  During this therapy, a catheter is inserted into the void left after the visible tumor is surgically removed. This catheter glows once the laser is switched on. The resultant light activates a drug that kills any cancer cells left inside the surrounding brain tissues. The drug is contained inside the…

Continue Reading

ThursdayFeb 05, 2026 10:00 am

Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies

Researchers have developed a technological platform that leverages yeast cells to test and understand new cancer treatments under development. The use of this platform promises to significantly reduce the costs and time needed in the drug development process.  Traditionally, immunotherapy treatments required several months to be tested in the lab. With this new method, the testing period could be collapsed to just a matter of days or a few weeks.  The findings of this research appeared in the Nature Communications journal and feature the technology dubbed yeast surface display. The system involves using modified yeast cells to behave and respond in a similar way to the behavior and responses of immune…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000